Documents to download

The regulations for medicines and medical devices in the UK are currently set at a European level. All medicines must be authorised by either the European Medicines Agency (EMA) or the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) on the basis of EU standards. In practice, the two bodies work together to assess medicines before authorisation and to monitor them afterwards. Medical devices must also conform to EU standards.

Medicine regulation in the UK will be affected by its departure from the EU. Under the draft withdrawal agreement, during the transition period, cooperation between the MHRA and the EMA will continue, and following the transition period, the political declaration stated that the UK and EU would “explore the possibility of cooperation”. If the UK leaves with no deal, all products authorised at the European level would automatically be authorised in the UK, and the MHRA will take on the functions of the EMA for the UK.

Ongoing developments in medicine safety include the role of technology, for example in analysing multiple databases on patient and drug experiences. Others include new methods of introducing drugs, new processes for clinical trials and enhanced education and training on safety regulation.

In February 2018, following incidents of side effects from three products, the Government launched the Independent Medicines and Medical Devices Safety Review to recommend improvements to the response to patient reports about harmful side effects. The review has so far taken evidence from a variety of sources, but has not announced a date for the publication of its main findings.

Finally, medicine safety can be seen in the context of wider patient safety initiatives. Several government and non-governmental bodies are working in this area, most prominently NHS Improvement, which is developing a new patient safety strategy.

Documents to download

Related posts

  • Community care for people with learning disabilities and/or autism

    Since 2012, successive governments have set targets to reduce the number of people with learning disabilities and/or autism in inpatient settings, in favour of being cared for in the community. However, though progress has been made, to date these targets have not been achieved. Leading in turn to calls for further action and investment, and for funding incentives to ensure those with learning disabilities and/or autism are cared for in the most appropriate settings.

    Community care for people with learning disabilities and/or autism
  • COP26: changes to the ‘green book’

    On 28 October 2021, Baroness Bennett of Manor Castle (Green party) is due to ask Her Majesty’s Government “what changes, if any, they plan to make to HM Treasury’s green book and related guidance to demonstrate global leadership as chair of COP26”. This article provides an overview of COP26 alongside an explanation of the ‘green book’ and recent changes made to it aimed at supporting the UK’s net zero target.

    COP26: changes to the ‘green book’
  • Coronavirus Act 2020: debate on temporary provisions

    As the Covid-19 pandemic progressed in March 2020, the Coronavirus Act 2020 came into force. This provided UK public bodies with a suite of powers to respond to the situation. Most provisions within the act are temporary and set to expire automatically in March 2022. The act requires these provisions to be scrutinised by Parliament periodically. This article considers what the act does, how it is scrutinised, and the UK and devolved governments’ Covid-19 plans for autumn/winter 2021–22.

    Coronavirus Act 2020: debate on temporary provisions